Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

afabicin MeSH Supplementary Concept Data 2025


MeSH Supplementary
afabicin
Unique ID
C000657127
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000657127
Entry Term(s)
(6-((1E)-3-(Methyl((3-methyl-1-benzofuran-2-yl)methyl)amino)-3-oxo-1-propen-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate
2-Propenamide, N-methyl-N-((3-methyl-2-benzofuranyl)methyl)-3-(5,6,7,8-tetrahydro-7-oxo-8-((phosphonooxy)methyl)-1,8-naphthyridin-3-yl)-, (2E)-
AFN-1720
Debio 1450
Debio1450
Pharm Action
Anti-Bacterial Agents
Registry Numbers
DMM8663H2R
Heading Mapped to
*Benzofurans
*Naphthyridines
Frequency
4
Note
antibiotic which targets the staphylococcal enoyl-acyl carrier protein reductase (FabI) and exhibits selective potent antibacterial activity against staphylococcal species, including methicillin-resistant Staphylococcus aureus
Source
Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01669-18.
Date of Entry
2020/02/11
Revision Date
2022/11/02
afabicin Preferred
Debio 1450 Related
page delivered in 0.004s